Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables: 2021-2025

Historic Receivables for BridgeBio Pharma (BBIO) over the last 1 years, with Sep 2025 value amounting to $116.5 million.

  • BridgeBio Pharma's Receivables was N/A to $116.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.4 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2024, which is 100.85% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Receivables of $116.5 million as of Q3 2025, which was up 51.58% from $76.9 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Receivables peaked at $116.5 million during Q3 2025, and registered a low of $2.4 million during Q4 2023.
  • In the last 3 years, BridgeBio Pharma's Receivables had a median value of $76.9 million in 2025 and averaged $63.1 million.
  • Data for BridgeBio Pharma's Receivables shows a peak YoY skyrocketed of 100.85% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows BridgeBio Pharma's Receivables stood at $10.2 million in 2021, then reached $2.4 million in 2023, then soared by 100.85% to $4.7 million in 2024, then reached $116.5 million in 2025.
  • Its Receivables stands at $116.5 million for Q3 2025, versus $76.9 million for Q2 2025 and $115.3 million for Q1 2025.